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Abstract
Background. Minimal change nephrotic syndrome
(MCNS) is the most frequent form of nephrotic
syndrome in childhood. In the glomerular basement
membrane (GBM) of adult patients with MCNS, a
reduced expression of a specific heparan sulphate (HS)
domain has been reported. In children with MCNS,
urinary activity of the HS-degrading enzyme hepar-
anase was increased. It is, therefore, possible that a
decreased GBM HS expression is associated with the
pathogenesis of proteinuria in patients with MCNS.
Methods. In this study, HS in glomeruli of five adult
and six paediatric patients with MCNS were analysed
by immunofluorescence staining using four different
antibodies, each defining a specific sulphated HS
domain. The pediatric patients were subdivided into
three groups depending on the presence or absence of
podocyte foot process effacement, the level of protei-
nuria and prednisone administration at the time of the
biopsy. In addition, kidneys of rats with adriamycin
nephropathy (ADRN), a model for MCNS, were
included in the study.
Results. Expression of sulphated HS domains was not
aberrant in adult or paediatric patients compared with
control subjects. Children with and without protein-
uria had the same HS content. In contrast, rats with
ADRN showed a decreased glomerular expression of
sulphated HS domains.
Conclusions. These results suggest that in patients with
MCNS proteinuria is not associated with major
changes in glomerular expression of sulphated HS
domains.
Keywords: heparan sulphate; immunofluorescence
staining; kidney; minimal change nephrotic
syndrome; proteinuria, sulphation
Introduction
Minimal change nephrotic syndrome (MCNS), which is
characterized by podocyte abnormalities and protein-
uria [1,2], is the most frequent cause of nephrotic
syndrome in childhood. This disease is proposed to be a
disorder of T-cell dysfunction and the increased
glomerular permeability may be due to a factor
secreted from activated T-cells. The pathogenic cyto-
kine, however, has not yet been identified.
It has been reported that loss of albumin into the
urine is largely a result of loss of charge-selective
permselectivity [3,4]. A reduction of fixed negative
charges in the glomerular capillary wall has been
noted [3,5]. The glycosaminoglycan heparan sulphate
(HS) in the glomerular basement membrane (GBM) is
assumed to be a major charge-selective component
of the filtration barrier. The long, unbranched HS
chains are composed of alternating glucosamine and
D-glucuronic/L-iduronic acid residues, which are
negatively charged due to the presence of multiple
carboxylic groups and N–, 2–O–, 6–O–, and 3–O–
sulphate groups [6]. In adult patients with MCNS, loss
of HS in the GBM has been reported, whereas
expression of the core protein of agrin, the major
heparin sulfate protoglycans (HSPG) in the GBM, was
not altered [7]. In children with steroid-sensitive
nephrotic syndrome, urinary activity of heparanase,
the endo-b-D-glucuronidase that catalyses the hydro-
lytic cleavage of HS, was found to be increased during
relapse compared with patients with MCNS in
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remission and control subjects. Urinary activity of
heparanase was decreased in adult patients in remis-
sion and relapse compared with control subjects. The
mRNA expression of heparanase by peripheral blood
mononuclear cells was unaltered [8]. Another study
showed that in co-culture with human glomerular
epithelial cells (podocytes), peripheral blood mono-
nuclear cells from patients with MCNS reduced the
synthesis of secreted and cellular GAGs by the
podocytes [9]. Taken together, these results indicate
that an aberrant expression of HS in the GBM of
patients with MCNS may contribute to the develop-
ment of proteinuria. Therefore, in the present study, we
investigated whether the pathogenesis of proteinuria in
adult as well as paediatric patients with MCNS is
associated with a decrease in glomerular HS expression
using five different antibodies, defining specific HS
domain structures.
Subjects and methods
Subjects
Kidney biopsies of five adult and six paediatric patients with
MCNS were obtained from the Division of Nephrology and
the Department of Pediatric Nephrology (Radboud
University Nijmegen Medical Centre, Nijmegen,
The Netherlands), respectively. The biopsies were taken
after informed consent from all subjects.
Characteristics of the adult patients are summarized in
Table 1. At the time of the biopsy, all patients had foot
process effacement and proteinuria. None of the patients had
received prednisone before the biopsy. Control renal tissue
was obtained from either donor kidneys, which were not
suitable for transplantation for anatomical reasons (n¼ 3), or
from histologically normal parts of a kidney removed for
renal adenocarcinoma (n¼ 1).
Table 2 summarizes the clinical characteristics of the
paediatric patients. All patients were initially treated with
prednisone. Frequently relapsing (i.e. two or more relapses
within the first 6 months after the first attack, or four or
more relapses in any 12-month period) as well as steroid-
dependent patients [i.e. two consecutive relapses, or two of
four relapses in any 6-month period, when a (usually
reduced) dose of steroid is still given, or within 2 weeks of
stopping steroid treatment] were included in the study.
Three patient groups (n¼ 2 per group) were formed
depending on the presence or absence of podocyte foot
process effacement [visualized by electron microscopy (see
subsequently)], the level of proteinuria, and prednisone
administration at the day of the biopsy (Table 2). The
following three groups were studied: (1) MCNS in remission,
which is characterized by absence of foot process effacement,
no proteinuria, but prednisone administration; (2) MCNS in
relapse, which is characterized by foot process effacement,
proteinuria, but no prednisone administration and
(3) MCNS in relapse with steroid treatment, which is
characterized by foot process effacement, proteinuria and
prednisone administration. The biopsies in the patients
Table 1. Clinical characteristics of the adult patients with minimal change nephrotic syndrome
Subject Sex Age at biopsy
(years)
Podocyte foot
process effacement
Selectivity index at
time of biopsy
Proteinuria at time
of biopsy (g/day)
Prednisone dose at
time of biopsy
1 9 51 þ 0.05 4.4 
2 9 28 þ 0.19 9.1 
3 9 75 þ 0.11 6.9 
4 8 77 þ <0.20 5–10 
5 8 71 þ >0.20 15.0 
Selectivity index¼ clearance of IgG/clearance of albumin. Selectivity index< 0.10: very selective proteinuria; selectivity index> 0.20:
a-selective proteinuria.
þ, present; , not present.
Table 2. Clinical characteristics of the paediatric patients with minimal change nephrotic syndrome
Subject Sex Age at biopsy Indication
biopsy
Podocyte foot
process effacement
Proteinuria at time
of biopsy (g/l)
Prednisone dose at
time of biopsy
MCNS in remission
1 8 6 y 10m FR   15mg/2 days
2 9 3 y 5m FR   15mg/day
MCNS in relapse
1 8 5 y 0m FR þ 1.5 
2 8 2 y 8m SD þ 2.1 
MCNS in relapseþ prednisone
1 8 4 y 0m FR þ 7.0 30mg/day
2 9 5 y 11m SD þ 16.5 60mg/day
MCNS, minimal change nephrotic syndrome; y, years; m, months; FR, frequently relapsing; SD, steroid-dependent;
þ, present; , not present.
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in remission, which were frequently relapsing, were per-
formed as preparations for cyclophosphamide therapy.
Renal tissue obtained from a boy biopsied because of
postrenal anuria at the age of 3 years and 11 months was
used as an age-matched control. This subject had no
nephrotic syndrome, no proteinuria, no foot process efface-
ment and the anuria disappeared rapidly after correcting the
postrenal obstruction.
The human ethics committee of the Radboud University
Nijmegen Medical Centre approved the study.
Electron microscopy
Kidney tissue was fixed in 2.5% (v/v) glutaraldehyde in
0.1MNa-cacodylate buffer (pH 7.4) overnight at 48C. Tissue
was washed with 0.1MNa-cacodylate buffer and postfixed in
2% (w/v) osmiumtetroxide (Electron Microscopy Sciences,
Washington, PA, USA) in Palade buffer for 1 h. After
washing with Palade buffer, tissue was dehydrated in
ascending concentrations of ethanol, and embedded in
Epon (Merck, Darmstadt, Germany) following Luft’s
procedure. Ultrathin sections were prepared, which were
post-stained with 4% (w/v) uranyl acetate for 45min and
subsequently with lead citrate for 5min. Sections were
examined using a Jeol 1200 EX2 electron microscope.
Antibodies
Phage display-derived anti-HS antibodies were obtained by
biopanning against HS or heparin, using bovine kidney HS
(antibodies HS4C3 and HS3A8 or porcine intestinal mucosa
heparin (antibodies EW3D10 and EW4G2). Production of
single chain variable fragment anti-HS antibodies was
performed as described [10]. Characteristics of the antibodies
are depicted in Table 3.
Immunofluorescence staining
Human kidney biopsies were sliced to 2mm cryosections and
stored at 808C until use. After air-drying, non-specific
binding sites were blocked with PBS containing 2% (w/v)
bovine serum albumin and 0.05% (v/v) Tween-20 (blocking
buffer) for 20min. Cryosections were then incubated with
phage display-derived anti-HS antibodies in blocking buffer
for 1 h. All antibodies were first titered on normal human
kidney cryosections and used at the dilution that gave
maximal specific fluorescence and minimal background
staining. As a negative control, antibody MPB49 was used.
This antibody is >95% identical to the other antibodies,
but it is not reactive with HS and does not stain kidney tissue
sections. Bound antibodies were detected by incubation with
mouse IgG anti-VSV tag antibody P5D4 (1:10; Boehringer
Mannheim, Mannheim, Germany), followed by Alexa
488-conjugated goat anti-mouse IgG (1:200; Molecular
Probes, Eugene, OR), both for 45min. After each antibody
incubation, cryosections were washed three times for 5min
with PBS containing 0.1% (v/v) Tween-20. Finally,
cryosections were fixed in 100% (v/v) ethanol for 10 s,
air-dried and embedded in 10% (w/v) mowiol (Calbiochem,
La Jolla, CA).
Glomerular staining intensity was examined using a Zeiss
Axioscope microscope and scored semiquantitatively inde-
pendenly by two observers on a scale of 0–10 [0¼ no staining,
5¼ 50% staining, 10¼ 100% (maximum) staining]. The
number of glomeruli counted in adult renal tissue was as
follows: controls: n¼ 20; patient 1: n¼ 4; patient 2: n¼ 6;
patient 3: n¼ 6; patient 4: n¼ 2; patient 5: n¼ 4. The number
of glomeruli counted in paediatric biopsies was as follows:
control: n¼ 9; MCNS in remission A: n¼ 15, B: n¼ 16;
MCNS in relapse A: n¼ 7, B: n¼ 9; MCNS in relapseþ
prednisone A: n¼ 4, B: n¼ 8. Figures show the mean of
the scores of the two observers. Each observer gave a mean
score of all glomeruli per biopsy. Scoring between the two
observers was consistent as deduced from regression analysis
(r2¼ 0.80–0.90).
Adriamycin nephropathy animal model
Kidneys of male Wistar rats with adriamycin nephropathy
(ADRN) were included in the study. In this animal model
proteinuria and foot process effacement were observed.
Unilateral ADRN was induced by clipping the left renal
artery and vein through a midline abdominal incision,
followed by injection via the tail vein with 1.5mg/kg body
weight of adriamycin. After 12min, when adriamycin was
cleared from the circulation, the clamp was removed. Rats
were sacrificed after 6 and 12 weeks. Staining of the right
kidney, which was exposed to adriamycin, was compared
with that of the left kidney (control).
Statistical analysis
Differences between groups were determined by the
non-parametric Mann-Whitney U-test using GraphPad
Table 3. Characteristics of domain-specific anti-heparan sulphate antibodies
Antibody VH CDR3 sequence GAG used for selection Essential chemical groups
HS4C3 GRRLKD bovine kidney HS NS, 6OS, 3OS
HS3A8 GMRPRL bovine kidney HS IdoA, NS, 2OS, 6OS (likely)
EW3D10 GRTVGRN porcine intestinal mucosa heparin S required, position(s) unknowna
EW4G2 GKVKLPN porcine intestinal mucosa heparin S required, position(s) unknowna
MPB49 WRNDRQ – –
Given are the antibody name, amino acid sequence of the VH complementary determining region 3 (CDR3), the GAG used for selection and
the preferred binding residues.
aAlthough the chemical nature of the specific HS/heparin structure recognized is not exactly known, the antibody defines a unique sulphated
HS structure as demonstrated by its specific staining pattern on rat renal cryosections.
HS(PG), heparan sulphate (proteoglycan); IdoA, iduronic acid; S, sulphate; NS, N-sulphate; 2OS, 2-O-sulphate; 6OS, 6-O-sulphate,
3OS: 3-O-sulphate.
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Prism 4.0 (GraphPad Software, Inc., San Diego, CA, USA).
Statistical significance was regarded if P< 0.05. Statistical
analysis for the paediatric MCNS patients was not possible
due to the small numbers of patients/group.
Results
The expression of HS in the GBM and mesangium
of adult patients with MCNS was evaluated by
immunofluorescence staining using a number of
phage display-derived anti-HS antibodies, each defin-
ing a different sulphated HS domain. In control
subjects, antibodies HS4C3, HS3A8, EW3D10
and EW4G2 showed a strong staining predominantly
of the mesangial matrix, but also along the GBM.
Expression was unaltered in glomeruli of patients
with MCNS (Figure 1).
In addition to adult patients, paediatric patients with
MCNS were included in the study. Different groups
were made, based on the presence or absence of
podocyte foot process effacement, level of proteinuria
and prednisone administration. The MCNS patients
in remission showed a normal renal ultrastructure.
The three layers of the glomerular capillary wall
formed by the fenestrated endothelial cells, the GBM
and the podocyte foot processes, were clearly visible
by routine electron microscopy. In contrast, the
renal biopsies of the patients with MCNS in relapse
showed obvious foot process effacement (Figure 2).
Immunofluorescence staining with the phage display-
derived anti-HS antibodies revealed no consistent
differences in staining intensity between the
MCNS patients and the control subject (Figure 3).
In proteinuric patients with or without prednisone
(MCNS in relapseþ prednisone and MCNS in relapse,
respectively) the profile of sulphated HS was also
not different from the patients without proteinuria
(MCNS in remission).
Taken together, no major differences in glomerular
staining for HS could be detected by the different
antibodies used. The staining procedure with the
phage display-derived antibodies used was appropriate
as we found a significantly reduced staining of HS
Fig. 1. Expression of sulphated HS domains in kidneys of adult control subjects and MCNS patients. (A) Immunofluorescence staining of
renal tissue with anti-HS antibodies HS4C3, HS3A8, EW3D10 and EW4G2. Bar: 50 mm; magnification is identical for each photograph.
(B) Quantification of immunofluorescence staining in arbitrary units (AU). The mean score of all glomeruli per biopsy is given. Note that
glomerular HS staining is not aberrant in the patients.
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with antibody HS4C3 in glomeruli of rats with
ADRN (Figure 4).
Discussion
In adult patients with MCNS, loss of HS, but not of
the core protein of agrin, which is the major HSPG in
the GBM, has been reported [7]. In this study,
we further investigated whether glomerular HS expres-
sion is aberrant in adult and paediatric patients with
MCNS using immunofluorescence staining. The
strength of our study is that we used four different
anti-HS antibodies, each defining a specific sulphated
HS domain, and analysed HS expression in paediatric
patients with MCNS in different clinical conditions.
No distinctions between different groups were made
in the study of van den Born et al. [7] on HS in
MCNS. With the tools used here, no significant
differences in glomerular expression of sulphated HS
domains could be detected in adult patients. Also, no
major decrease was observed for the paediatric patients
irrespective of the presence or absence of podocyte
foot process effacement, level of proteinuria and
prednisone administration. In paediatric patients
with steroid-sensitive nephrotic syndrome, urinary
activity of heparanase was increased during relapse,
but not during remission [8]. However, amounts of
HS excreted into the urine were not aberrant [11],
which supports our observation that no HS has
been removed from the glomeruli of paediatric patients
with MCNS.
It has been noticed that proteinuria in MCNS is
largely a result of loss of charge-selective permselec-
tivity [3,4]. HS in the GBM has been assumed to play
an important role in preventing urinary loss of albumin
by providing fixed negative charges to the glomerular
capillary wall. However, recent data indicate that HS
does not play a direct major role in the charge-selective
barrier properties of the GBM. Removal of HS
from the GBM by injection of Wistar rats with the
bacterial HS-degrading enzyme heparinase III did
not result in proteinuria [12]. In podocyte-specific
agrin (major HSPG in the GBM) knock-out mice, no
proteinuria was observed [13], which was also the case
for mice lacking the HS-bearing, exon 3-coded, part of
perlecan (minor HSPG in the GBM) [14]. Transgenic
mice overexpressing human heparanase only had
slightly elevated levels of proteinuria [15]. In addition,
it should be noted that no aberrant glomerular HS
expression was detected in proteinuric patients with
congenital nephrotic syndrome of the Finnish type [16]
or IgA nephropathy [7]. Taken together, these obser-
vations indicate that other mechanisms than a decrease
in glomerular HS expression probably contribute to
the development of proteinuria in patients with
MCNS.
If proteinuria in MCNS is not the result of loss of
sulphated HS, what may then be its cause? The
observations of podocyte foot process effacement
[1,2,17], a decrease in the number of slit diaphragms
[2], and possible decreased expression and/or redis-
tribution of the slit diaphragm-associated protein
nephrin [1,17] and the podocytic protein synaptopodin
[18] in MCNS suggest that the podocyte and/or slit
diaphragm have a role in the defective function of
the glomerular filtration barrier. In addition, a- and
b-dystroglycans were reduced in relapsing MCNS,
but returned to normal after steroid treatment [19],
indicating that proteinuria in MCNS may also be
the result of a decreased adhesion of podocytes to
the GBM.
If there is no loss of sulphated HS in the GBM of
patients with MCNS, how then can the observed
reduction of fixed negative charges in the glomerular
capillary wall be explained? Experimental MCNS,
induced by injection of rats with puromycin aminonu-
cleoside, was characterized by the loss of negatively
Fig. 2. Ultrastructure of glomeruli from paediatric patients with minimal change nephrotic syndrome in relapse and in remission. Note the
podocyte foot process effacement in a patient in relapse, but not in a patient in remission. Bar: 2 mm; magnification is identical for each
photograph.
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Fig. 3. Expression of sulphated HS domains in kidneys of a paediatric control subject and MCNS patients in remission, relapse and relapse
with prednisone treatment. (A, C) Immunofluorescence staining of renal tissue with anti-HS antibodies HS4C3 (A) and EW4G2 (C).
Bar: 50 mm; magnification is identical for each photograph. (B, D, E, F) Quantification of immunofluorescence staining with HS4C3 (B),
EW4G2 (D), HS3A8 (E) and EW3D10 (E) in arbitrary units (AU). The mean score of all glomeruli per biopsy is given. Note that glomerular
HS staining is not aberrant in any patient group.
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charged neuraminic acid residues, attached to the
protein podocalyxin, which is predominantly expressed
at the podocyte cell surface, but also in the endothelial
glycocalyx [20, 21]. In paediatric MCNS patients
with proteinuria, a very weak to absent glomerular
reactivity of colloidal iron, reported to be specific
for neuraminic acid, was detected [20]. In addition,
removal of glomerular neuraminic acid after injection
of mice and rats with the enzyme neuraminidase
resulted in proteinuria [12]. Furthermore, recently,
it was found in cell culture studies that removal of
neuraminic acid from the endothelial glycocalyx
increased the passage of albumin [23]. These results
indicate that neuraminic acid in the endothelial
glycocalyx and/or at the podocyte cell surface may be
an important determinant for the charge-selective
properties of the glomerular capillary wall, and be
involved in the pathophysiology of MCNS.
To conclude, no major alterations in glomerular
expression of sulphated HS domains were observed in
paediatric patients with MCNS irrespective of the
presence or absence of podocyte foot process efface-
ment, the level of proteinuria and prednisone admin-
istration. In adult patients, sulphated HS domains were
also not aberrant. These results indicate that protein-
uria observed in adult as well as paediatric patients
with MCNS may not be due to major alterations in
glomerular expression of sulphated HS domains.
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